Payment & Shipping Terms:
|Store:||Cool Dry Place||Shelf Life:||2 Years|
|Usage:||Brain Use||Shipping Time:||7-12 Days|
|Form:||Powder Or Pills|
brain enhancing supplements,
nootropic brain supplements
Chemical name:Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate
Synonyms:PRL-8053;PRL-8-53;Methyl 3-(2-(benzyl(Methyl)aMino)ethyl)benzoate hydrochloride;3-(2-Benzyl(methyl)aminoethyl)benzoic acid methyl ester hydrochloride;m-[2-(Benzylmethylamino)ethyl]benzoic acid methyl ester hydrochloride;Benzoic acid, 3-(2-(Methyl(phenylMethyl)aMino)ethyl)-, Methyl ester, hydrochloride
Subjects in human trials have been given up to 100 mg a day and did not appear to develop any negative side effects
The effect of 3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride (PRL-8-53) on learning and on retention of verbal information in human subjects was investigated. Using the serial anticipation method under double-blind conditions it was found that PRL-8-53 causes slight improvement of acquisition. Retinetion of verbal information was found improved to a statistically significant degree (most P values better than 0.01, some better than 0.001). No significant changes were found for either visual reaction time or motor control after drug when compared with placebo values.
PRL-8-53 (chemical name Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate) is a synthetic nootropic compound discovered in 1972 and patented in 1975 by the late Dr. Nikolaus Hansl, a neuropharmacologist at Creighton University in Omaha, Nebraska. Preliminary animal tests indicated that the compound was both safe and significantly nootropic, boosting avoidance learning in rodents with no adverse effects. But the real interest in PRL-8-53 was sparked by a 1978 study on human volunteers, which showed that a single dose of the compound could improve word retention scores by more than 200%.
HOW IT WORKS
PRL-8-53's exact mechanisms of action are not well understood, but it is generally believed to regulate the brain's production of and response to several crucial neurotransmitters. In his reports on human and animal studies Hansl indicated that PRL-8-53 potentiates dopamine, partially restricts production of serotonin, and enhances the brain's response to acetylcholine.
Though Hansl's research report on the 1978 human study suggests those actions, it does not clearly delineate the mechanism of action.The fact that older subjects saw the most nootropic benefit from taking the drug supports the concept that dopamine modulation plays a major role in PLR-8-53's effects. Up-regulating the normal age-related lessening of dopamine production that is associated with cognitive decline could have a significant positive impact on both learning and memory.
The only human study on PRL-8-53 was based on the ingestion of a single 5 mg dose. There is no data on the effectiveness or potential toxicity of any other dosage in humans.
No adverse effects from a single 5 mg dose of PRL-8-53 were observed in the human study. Animal studies suggest that the compound has a high therapeutic threshold, but evidence is very limited because no comprehensive toxicity studies have been completed.
Increased Learning Ability
Improved Cognitive Processing